Founded in 1993
  Year: 1998 | Volume: 6 | Issue: 2 | Pages: 53-56
  Original Article
  HYDROSOLUBLE FULLERENE DERIVATIVE C60(OH)24 DOES NOT SUPPRESS THE PROLIFERATION OF MOUSE MELANOMA B16 CELLS AND HUMAN CERVIX CARCINOMA HELA CELLS IN VITRO
Zorica JURANIC, Jovana SIMIC-KRSTIC, Sinisa RADULOVIC
  DOI:
  Abstract:
  Background: Fullerenes are relatively new group of carbon compounds. Recent studies showed that newly synthesised hydrosoluble fullerenes exhibit various biological activities, including cytotoxicity against some tumor cells. The aim of this study was to investigate the antiproliferative action of water-soluble fullerene, C60(OH)24, against human cervix carcinoma, HeLa cells and mouse melanoma B16 cells.
Methods: Various numbers of target cells, grown alone, or in co-culture with human peripheral blood mononuclear cells (PBMC) were continuously treated with increasing concentrations of fullerene during one to three days. MTT test was used for the assessment of antiproliferative C60(OH)24 action.
Results: Treatment of HeLa cells with fullerene C60(OH)24 in concentration range (2.2-35.5 mM) for 20 h; 44 h; or 72 h and of B16 cells with C60(OH)24 (1,1-17.8 mM) for 72 h did not suppress survival of these cells. Investigated compound did not affect proliferation of HeLa cells grown alone or in mixed culture with human PBMC. There was no cytotoxic action of C60(OH)24 on B16 cells as a function of cell number seeded.
Conclusion: The antiproliferative action of fullerene polyhydroxylated derivative C60(OH)24 on B16 and HeLa cells grown in culture was not observed. Fullerene derivative C60(OH)24 in the range of concentration 2.2 mM to 35.5 mM did not suppress HeLa cells survival, independently on the presence or the absence of human PBMC in co-culture.
  Key words: HeLa cells; B16 cells; Human PBMC; MTT test; Fullerene C60(OH)24
  Read full text in PDF [Full Text]
Next article

Previous article

Table of contents

Browse all Volumes

Search all Volumes
By keywords
By authors

  Search AoO for:
 

  Related articles in AoO:
 
About Journal | Editorial Board | Editorial Policy | Instructions for Authors | Open Access | Advertising | Payed issues | Article Submission Charge | Contact
Founder, owner and publisher: Oncology Institute of Vojvodina, Serbia
Online since 1997 (Abstracts only); 2000 (Abstracts and Full text)
ISSN: 0354-7310 eISSN: 1450-9520